CoChat
Sign Up
Cited by 58

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues

Teschke, Rolf, Uetrecht, Jack·2021·Annals of Translational Medicine
DOI 10.21037/atm-2020-ubih-05PMC PMC8106057
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.21037/atm-2020-ubih-05

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Idiosyncratic DILI is complex, multifactorial, not predictable, species-specific, cannot be reproduced; the patient is the sole source of the study.

    “Idiosyncratic toxicity is more common. This is a complex, multifactorial disease that may involve factors associated with the poison, the patient, and/or the environment. They are not predictable and are species-specific; thus, they cannot be reproduced. As a consequence, the patient is the sole source of the study.”

    From Metabolomic Analysis of Pediatric Patients with Idiosyncratic Drug-Induced Liver Injury According to the Updated RUCAM (2023) · cites this paper as [2]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 132

  1. [1]Gao B Xu MJ Bertola A Animal models of alcoholic liver disease: pathogenesis and clinical relevance. Gene Expr 2017; 17: 173- 86. 10.3727/105221617X695519 28411363 PMC5500917 · DOI
  2. [2]Neuman MG French SW Zakhari S Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage. Exp Mol Pathol 2017; 102: 162- 80. 10.1016/j.yexmp.2017.01.003 28077318 · DOI
  3. [3]Perwaiz S Forrest D Mignault D Appearance of atypical 3 alpha,6 beta,7 beta,12 alpha-tetrahydroxy-5 beta-cholan-24-oic acid in spgp knockout mice. J Lipid Res 2003; 44: 494- 502. 10.1194/jlr.M200394-JLR200 12562825 · DOI
  4. [4]Teschke R. Alcoholic liver disease: alcohol metabolism, cascade of molecular mechanisms, cellular targets, and clinical aspects. Biomedicines 2018; 6: 106. 10.3390/biomedicines6040106 30424581 PMC6316574 · DOI
  5. [5]Teschke R. Alcoholic liver disease: current mechanistic aspects with focus on their clinical relevance. Biomedicines 2019; 7: 68. 10.3390/biomedicines7030068 31491888 PMC6783919 · DOI
  6. [6]Hasumura Y Teschke R Lieber CS. Increased carbon tetrachloride hepatotoxicity, and its mechanism, after chronic ethanol consum.ption. Gastroenterology 1974; 66: 415- 22. 10.1016/S0016-5085(74)80142-3 4149842 · DOI
  7. [7]Scholten D Trebicka J Liedtke C The carbon tetrachloride model in mice. Lab Anim 2015; 49: 4- 11. 10.1177/0023677215571192 25835733 · DOI
  8. [8]Teschke R. Aliphatic halogenated hydrocarbons: report and analysis of liver injury in 60 patients. J Clin Transl Hepatol 2018; 6: 350- 61. 10.14218/JCTH.2018.00040 30637211 PMC6328725 · DOI
  9. [9]Teschke R. Liver injury by carbon tetrachloride intoxication in 16 patients treated with forced ventilation to accelerate toxin removal via the lungs: A clinical report. Toxics 2018; 6: 25. 10.3390/toxics6020025 29702608 PMC6027346 · DOI
  10. [10]Weiskirchen R Lammert F. A yellow bullet against the drivers of hepatic fibrogenesis. Hepatology 2008; 48: 683- 5. 10.1002/hep.22457 18666259 · DOI
  11. [11]Weiskirchen R Meurer SK Liedtke C Mast cells in liver fibrogenesis. Cells 2019; 8: 1429. 10.3390/cells8111429 31766207 PMC6912398 · DOI
  12. [12]Gehrke SG Kulaksiz H Herrmann T Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron. Blood 2003; 102: 371- 6. 10.1182/blood-2002-11-3610 12637325 · DOI
  13. [13]Niederau C Fischer R Pürschel A Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110: 1107- 19. 10.1053/gast.1996.v110.pm8613000 8613000 · DOI
  14. [14]Merle U Schaefer M Ferenci P Clinical presentation, diagnosis and long-term outcome of Wilson’s disease: a cohort study. Gut 2007; 56: 115- 20. 10.1136/gut.2005.087262 16709660 PMC1856673 · DOI
  15. [15]Stremmel W Merle U Weiskirchen R. Clinical features of Wilson disease. Ann Transl Med 2019; 7: S61. 10.21037/atm.2019.01.20 31179298 PMC6531660 · DOI
  16. [16]Jing J Teschke R. Traditional Chinese Medicine and herb-induced liver injury: comparison with drug-induced liver injury. J Clin Transl Hepatol 2018; 6: 57- 68. 10.14218/JCTH.2017.00033 29577033 PMC5863000 · DOI
  17. [17]Shahbaz O Mahajan S Lewis JH. Highlights of drug- and herb- induced liver injury in the literature from 2016: how best to translate new information into clinical practice. Expert Opin Drug Metab Toxicol 2017; 13: 935- 51. 10.1080/17425255.2017.1362391 28772086 · DOI · Paper page
  18. [19]Zhu Y Niu M Chen J Comparison between Chinese herbal medicine and Western medicine-induced liver injury of 1985 patients. J Gastroenterol Hepatol 2016; 31: 1476- 1482. 10.1111/jgh.13323 26896664 · DOI · Paper page
  19. [20]Real M Barnhill MS Higley C Drug-induced liver injury: highlights of the recent literature. Drug Saf 2019; 42: 365- 87. 10.1007/s40264-018-0743-2 30343418 · DOI
  20. [21]Sarges P Steinberg JM Lewis JH. Drug-Induced Liver Injury: Highlights from a review of the 2015 literature. Drug Saf 2016; 39: 801- 21. 10.1007/s40264-016-0427-8 27142208 · DOI
  21. [22]Teschke R. Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method. Expert Opin Drug Metab Toxicol 2018; 14: 1169- 87. 10.1080/17425255.2018.1539077 30354694 · DOI · Paper page
  22. [23]Teschke R. Analysis of 46,266 cases assessed for causality by RUCAM and published from 2014 to early 2019. In: Special issue: Clinical drug induced liver injury: Current diagnostic and mechanistic challenges, guest editors: Rolf Teschke, Gaby Danan, James H. Lewis. Front Pharmacol 2019;10:730. PMC6664244 31396080
  23. [24]Uetrecht J. Mechanistic studies of idiosyncratic DILI: Clinical implications. Front Pharmacol 2019; 10: 837. 10.3389/fphar.2019.00837 31402866 PMC6676790 · DOI
  24. [25]Björnsson ES Hoofnagle JH. Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports. Hepatology 2016; 63: 590- 603. 10.1002/hep.28323 26517184 · DOI · Paper page
  25. [26]Björnsson ES. Hepatotoxicity by drugs: The most common implicated agents. Int J Mol Sci 2016; 17: 224. 10.3390/ijms17020224 26861310 PMC4783956 · DOI · Paper page
  26. [27]Shi Q Hong H Senior J Biomarkers for drug-induced liver injury. Expert Rev Gastroenterol Hepatol 2010; 4: 225- 34. 10.1586/egh.10.8 20350268 · DOI
  27. [28]Teschke R Frenzel C Wolff A Drug induced liver injury: accuracy of diagnosis in published reports. Ann Hepatol 2014; 13: 248- 55. 10.1016/S1665-2681(19)30888-9 24552867 · DOI
  28. [29]Teschke R Danan G. Drug induced liver injury with analysis of alternative causes as confounding variables. Br J Clin Pharmacol 2018; 84: 1467- 77. 10.1111/bcp.13593 29607530 PMC6005631 · DOI
  29. [30]Thakkar S, Chen M, Hong H, et al. Drug-induced liver injury (DILI) classification and its application on human DILI risk prediction. In: Chen M, Will Y. editors. Drug-Induced Liver Toxicity. Springer, 2018:45-59.
  30. [31]Teschke R, Danan G. Causality assessment methods in drug-induced liver injury. In: Chen M, Will Y. editors. Drug-induced liver toxicity. Springer, 2018:555-94.
  31. [32]Noureddin N, Kaplowitz N. Overview of mechanisms of drug-induced liver injury (DILI) and key challenges in DILI research. In: Chen M, Will Y. editors. Drug-Induced Liver Toxicity. Springer, 2018:3-18.
  32. [33]Danan G Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323- 30. 10.1016/0895-4356(93)90101-6 8229110 · DOI · Paper page
  33. [34]Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. nt J Mol Sci 2016;17:14. PMC4730261 26712744
  34. [35]Aithal GP Rawlins MD Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ 1999; 319: 1541. 10.1136/bmj.319.7224.1541 10591713 PMC28298 · DOI
  35. [36]Teschke R Eickhoff A Brown AC Diagnostic biomarkers in liver injury by drugs, herbs, and alcohol: tricky dilemma after EMA correctly and officially retracted Letter of Support. Int J Mol Sci 2019; 21: 212. 10.3390/ijms21010212 31892250 PMC6981464 · DOI · Paper page
  36. [38]Kleiner DE. Recent advances in the histopathology of drug-induced liver injury. Surg Pathol Clin 2018; 11: 297- 311. 10.1016/j.path.2018.02.009 29751876 PMC5953206 · DOI
  37. [39]Morán L Cubero FJ. Extracellular vesicles in liver disease and beyond. World J Gastroenterol 2018; 24: 4519- 26. 10.3748/wjg.v24.i40.4519 30386101 PMC6209575 · DOI
  38. [40]Urban SK Mocan T Sänger H Extracellular vesicles in liver diseases: diagnostic, prognostic, and therapeutic application. Semin Liver Dis 2019; 39: 70- 7. 10.1055/s-0038-1676122 30654391 · DOI
  39. [41]Bala S Petrasek J Mundkur S Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 2012; 56: 1946- 57. 10.1002/hep.25873 22684891 PMC3486954 · DOI
  40. [42]Cho YE Mezey E Hardwick JP Increased ethanol-inducible cytochrome P450-2E1 and cytochrome P450 isoforms in exosomes of alcohol-exposed rodents and patients with alcoholism through oxidative and endoplasmic reticulum stress. Hepatol Commun 2017; 1: 675- 90. 10.1002/hep4.1066 29404485 PMC5721437 · DOI
  41. [43]Gerth K Kodidela S Mahon M Circulating extracellular vesicles containing xenobiotic metabolizing CYP enzymes and their potential roles in extrahepatic cells via cell-cell interactions. Int J Mol Sci 2019; 20: 6178. 10.3390/ijms20246178 31817878 PMC6940889 · DOI
  42. [44]Gloor Y Schvartz D, F Samer C. Old problem, new solutions: biomarker discovery for acetaminophen liver toxicity. Expert Opin Drug Metab Toxicol 2019; 15: 659- 69. 10.1080/17425255.2019.1642323 31293190 · DOI · Paper page
  43. [45]Holman NS Mosedale M Wolf KK Subtoxic alterations in hepatocyte-derived exosomes: an early step in drug-induced liver injury. Toxicol Sci 2016; 151: 365- 75. 10.1093/toxsci/kfw047 26962055 PMC4880137 · DOI
  44. [46]Jeppesen DK Fenix AM Franklin JL Reassessment of exosome composition. Cell 2019; 177: 428- 445.e18. 10.1016/j.cell.2019.02.029 30951670 PMC6664447 · DOI · Paper page
  45. [47]Masyuk AI Masyuk TV Larusso NF. Exosomes in the pathogenesis, diagnostics and therapeutics of liver diseases. J Hepatol 2013; 59: 621- 5. 10.1016/j.jhep.2013.03.028 23557871 PMC3831338 · DOI
  46. [48]Ogese MO Jenkins RE Adair K Exosomal transport of hepatocyte-derived drug-modified proteins to the immune system. Hepatology 2019; 70: 1732- 49. 10.1002/hep.30701 31070244 PMC6899733 · DOI
  47. [49]Rahman MA Kodidela S Sinha N Plasma exosomes exacerbate alcohol- and acetaminophen-induced toxicity via CYP2E1 pathway. Sci Rep 2019; 9: 6571. 10.1038/s41598-019-43064-2 31024054 PMC6484097 · DOI
  48. [51]Teschke R. Microsomal ethanol-oxidizing system: success over 50 years and an encouraging future. Alcohol Clin Exp Res 2019; 43: 386- 400. 10.1111/acer.13961 30667528 · DOI
  49. [52]Starkey Lewis PJ Dear J Platt V Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 2011; 54: 1767- 76. 10.1002/hep.24538 22045675 · DOI
  50. [53]Cho YE Kim SH Lee BH Circulating plasma and exosomal micrornas as indicators of drug-induced organ injury in rodent models. Biomol Ther (Seoul) 2017; 25: 367- 73. 10.4062/biomolther.2016.174 28208010 PMC5499614 · DOI
  51. [54]Church RJ Watkins PB. Serum biomarkers of drug-induced liver injury: Current status and future directions. J Dig Dis 2019; 20: 2- 10. 10.1111/1751-2980.12684 30378260 · DOI · Paper page
  52. [55]Enache LS Enache EL Ramière C Circulating RNA molecules as biomarkers in liver disease. Int J Mol Sci 2014; 15: 17644- 66. 10.3390/ijms151017644 25272224 PMC4227182 · DOI
  53. [56]Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology 2014; 146: 914- 28. 10.1053/j.gastro.2013.12.032 24389305 PMC4031195 · DOI
  54. [57]Krauskopf J, Kleinjans J, de Kok TM. Circulating microRNAs as novel biomarkers of drug-induced liver injury in humans. In: Chen M, Will Y, editors. Drug-Induced Liver Toxicity. Springer, 2018:597-610.
  55. [58]Li LM Wang D Zen K. MicroRNAs in drug-induced liver injury. J Clin Transl Hepatol 2014; 2: 162- 9. 26357624 PMC4521241
  56. [59]McGill MR Jaeschke H. MicroRNAs as signaling mediators and biomarkers of drug- and chemical-induced liver injury. J Clin Med 2015; 4: 1063- 78. 10.3390/jcm4051063 26167291 PMC4470217 · DOI
  57. [60]Thulin P Nordahl G Gry M Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts. Liver Int 2014; 34: 367- 78. 10.1111/liv.12322 24118944 · DOI
  58. [61]Antoine D. Translational and mechanistic biomarkers of drug-induced liver injury - Candidates and qualification strategies. In: Chen M, Will Y. editors. Drug-Induced Liver Toxicity. Springer, 2018:533-53.
  59. [62]Senior JR. New biomarkers for drug-induced liver injury: are they really better? What do they diagnose. Liver Int 2014; 34: 325- 7. 10.1111/liv.12384 25839081 · DOI
  60. [63]Teschke R Schulze J Eickhoff A Drug induced liver injury: can biomarkers assist RUCAM in causality assessment. Int J Mol Sci 2017; 18: 803. 10.3390/ijms18040803 28398242 PMC5412387 · DOI
  61. [64]Vliegenthart ADB Berends C Potter CMJ MicroRNA-122 can be measured in capillary blood which facilitates point-of-care testing for drug-induced liver injury. Br J Clin Pharmacol 2017; 83: 2027- 33. 10.1111/bcp.13282 28257154 PMC5555871 · DOI
  62. [65]Konturek PC Harsch IA Konturek K Gut−liver axis: How do gut bacteria influence the liver. Med Sci (Basel) 2018; 6: 79. 10.3390/medsci6030079 30227645 PMC6165386 · DOI · Paper page
  63. [67]Cani PD. Human gut microbiome: hopes, threats and promises. Gut 2018; 67: 1716- 25. 10.1136/gutjnl-2018-316723 29934437 PMC6109275 · DOI · Paper page
  64. [69]Zhang J Wang R. Gut microbiota modulates drug pharmacokinetics. Drug Metab Rev 2018; 50: 357- 68. 10.1080/03602532.2018.1497647 30227749 · DOI
  65. [70]Borkham-Kamphorst E Van de Leur E Haas U Liver parenchymal cells lacking Lipocalin 2 (LCN2) are prone to endoplasmic reticulum stress and unfolded protein response. Cell Signal 2019; 55: 90- 9. 10.1016/j.cellsig.2019.01.001 30615971 · DOI
  66. [71]Su GL Gong KQ Fan MH Lipopolysaccharide-binding protein modulates acetaminophen-induced liver injury in mice. Hepatology 2005; 41: 187- 95. 10.1002/hep.20533 15619225 · DOI
  67. [72]Teschke R Zhu Y. Opinion: Intestinal microbiome, endotoxins, cytochrome P450 2E1, and the gut-liver axis in alcoholic liver disease. EC Gastroenterology Dig Syst 2019; 6: 66- 75.
  68. [73]Tacke F. Targeting hepatic macrophages to treat liver diseases. J Hepatol 2017; 66: 1300- 12. 10.1016/j.jhep.2017.02.026 28267621 · DOI · Paper page
  69. [74]Dragoi D Benesic A Pichler G Proteomics analysis of monocyte-derived hepatocyte-like cells identifies Integrin Beta 3 as a specific biomarker for drug-induced liver injury by diclofenac. Front Pharmacol 2018; 9: 699. 10.3389/fphar.2018.00699 30022949 PMC6039575 · DOI
  70. [75]Iorga A, Dara L, Kaplowitz N. Drug-Induced Liver Injury: Cascade of events leading to cell death, apoptosis or necrosis. In special issue: Molecular Research on Drug Induced liver Injury, academic editors: Rolf Teschke and Gaby Danan. Int J Mol Sci 2017;18:1018. PMC5454931 28486401
  71. [76]Uetrecht J. Immunoallergic drug-induced liver injury in humans. Semin Liver Dis 2009; 29: 383- 92. 10.1055/s-0029-1240007 19826972 · DOI
  72. [77]Uetrecht J Naisbitt DJ. Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev 2013; 65: 779- 808. 10.1124/pr.113.007450 23476052 PMC3639727 · DOI
  73. [78]Tacke F Zimmermann HW. Macrophage heterogeneity in liver injury and fibrosis. J Hepatol 2014; 60: 1090- 6. 10.1016/j.jhep.2013.12.025 24412603 · DOI · Paper page
  74. [79]Kalra BS. Cytochrome P450 enzyme isoforms and their therapeutic implications: an update. Indian J Med Sci 2007; 61: 102- 16. 10.4103/0019-5359.30351 17259690 · DOI
  75. [80]Sychev DA Ashraf GM Svistunov AA The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo. Drug Des Devel Ther 2018; 12: 1147- 56. 10.2147/DDDT.S149069 29780235 PMC5951216 · DOI
  76. [81]Foti RS Dalvie DK. Cytochrome P450 and non-cytochrome P450 oxidative metabolism: contributions to the pharmacokinetics, safety, and efficacy of xenobiotics. Drug Metab Dispos 2016; 44: 1229- 45. 10.1124/dmd.116.071753 27298339 · DOI
  77. [82]Regan SL Maggs JL Hammond TG Acyl glucuronides: the good, the bad and the ugly. Biopharm Drug Dispos 2010; 31: 367- 95. 10.1002/bdd.720 20830700 · DOI
  78. [83]Acocella G. Pharmacokinetics and metabolism of rifampin in humans. Rev Infect Dis 1983; 5 Suppl 3: S428- 32. 10.1093/clinids/5.Supplement_3.S428 6356276 · DOI
  79. [84]Amano T Fukami T Ogiso T Identification of enzymes responsible for dantrolene metabolism in the human liver: A clue to uncover the cause of liver injury. Biochem Pharmacol 2018; 151: 69- 78. 10.1016/j.bcp.2018.03.002 29522712 · DOI
  80. [85]Andrade C Freitas L Oliveira V. Twenty-six years of HIV science: an overview of anti-HIV drugs metabolism. Braz J Pharmaceut Sci 2011; 47: 209- 30. 10.1590/S1984-82502011000200003 · DOI
  81. [86]Back DJ Tjia JF Karbwang J In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br J Clin Pharmacol 1988; 26: 23- 9. 10.1111/j.1365-2125.1988.tb03359.x 3203057 PMC1386495 · DOI
  82. [87]Bertz RJ Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32: 210- 58. 10.2165/00003088-199732030-00004 9084960 · DOI
  83. [88]Björnsson E Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42: 481- 9. 10.1002/hep.20800 16025496 · DOI · Paper page
  84. [89]Choughule KV Barnaba C Joswig-Jones CA In vitro oxidative metabolism of 6-mercaptopurine in human liver: insights into the role of the molybdoflavoenzymes aldehyde oxidase, xanthine oxidase, and xanthine dehydrogenase. Drug Metab Dispos 2014; 42: 1334- 40. 10.1124/dmd.114.058107 24824603 PMC4109211 · DOI
  85. [90]Das KM Chowdhury JR Zapp B Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats. Gastroenterology 1979; 77: 280- 4. 10.1016/0016-5085(79)90277-4 36326 · DOI
  86. [91]Dekker SJ Dohmen F Vermeulen NPE Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin: inhibition of CYP3A-catalysed hydroxylation by sulfaphenazole. Br J Pharmacol 2019; 176: 466- 77. 10.1111/bph.14548 30447161 PMC6329626 · DOI
  87. [92]Desta Z Saussele T Ward B Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 2007; 8: 547- 58. 10.2217/14622416.8.6.547 17559344 · DOI
  88. [93]Donehower RC. Metabolic conversion of methotrexate in man. Recent results. Cancer Res 1980; 74: 37- 41. 10.1007/978-3-642-81488-4_5 7444148 · DOI
  89. [94]Dybing E Nelson SD Mitchell JR Oxidation of alpha-methyldopa and other catechols by cytochrome P-450-generated superoxide anion: possible mechanism of methyldopa hepatitis. Mol Pharmacol 1976; 12: 911- 20. 187927
  90. [95]Erickson DA Mather G Trager WF Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999; 27: 1488- 95. 10570031
  91. [96]Fatunde OA Brown SA. The role of CYP450 Drug metabolism in precision cardio-oncology. Int J Mol Sci 2020; 21: 604. 10.3390/ijms21020604 31963461 PMC7014347 · DOI
  92. [97]Hautekeete ML Horsmans Y Van Waeyenberge C HLA association of amoxicillin-clavulanate--induced hepatitis. Gastroenterology 1999; 117: 1181- 6. 10.1016/S0016-5085(99)70404-X 10535882 · DOI
  93. [98]Heidari R Niknahad H Jamshidzadeh A An overview on the proposed mechanisms of antithyroid drugs-induced liver injury. Adv Pharm Bull 2015; 5: 1- 11. 25789213 PMC4352210
  94. [100]Johansson I Ingelman-Sundberg M. Genetic polymorphism and toxicology - with emphasis on cytochrome p450. Toxicol Sci 2011; 120: 1- 13. 10.1093/toxsci/kfq374 21149643 · DOI
  95. [101]Kiang TK Ho PC Anari MR Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol Sci 2006; 94: 261- 71. 10.1093/toxsci/kfl096 16945988 · DOI
  96. [102]Kim JH Choi WG Lee S Revisiting the metabolism and bioactivation of ketoconazole in human and mouse using liquid chromatography-mass spectrometry-based metabolomics. Int J Mol Sci 2017; 18: 621. 10.3390/ijms18030621 28335386 PMC5372636 · DOI
  97. [103]Landowski CP Song X Lorenzi PL Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism. Pharm Res 2005; 22: 1510- 8. 10.1007/s11095-005-6156-9 16132363 · DOI
  98. [104]LiverTox. Clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. infliximab. Last updated 10 February 2017. Available online: https//www.nbci.nim.nih.gov/books/. Accessed 15 April 2020. 31643176
  99. [105]Myers AL Kawedia JD Champlin RE Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. Expert Opin Drug Metab Toxicol 2017; 13: 901- 23. 10.1080/17425255.2017.1360277 28766962 PMC5584057 · DOI
  100. [106]Nelis HJ De Leenheer AP. Metabolism of minocycline in humans. Drug Metab Dispos 1982; 10: 142- 6. 6124399
  101. [107]Okuno H Kitao Y Takasu M Depression of drug metabolizing activity in the human liver by interferon-alpha. Eur J Clin Pharmacol 1990; 39: 365- 7. 10.1007/BF00315411 2076719 · DOI
  102. [108]Scott LM Durant P Leone-Kabler S Effects of prior oral contraceptive use and soy isoflavonoids on estrogen-metabolizing cytochrome P450 enzymes. J Steroid Biochem Mol Biol 2008; 112: 179- 85. 10.1016/j.jsbmb.2008.10.001 18955142 PMC2646417 · DOI
  103. [109]Shi J Montay G Bhargava VO. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet 2005; 44: 915- 34. 10.2165/00003088-200544090-00003 16122280 · DOI
  104. [110]Shih TY Pai CY Yang P A novel mechanism underlies the hepatotoxicity of pyrazinamide. Antimicrob Agents Chemother 2013; 57: 1685- 90. 10.1128/AAC.01866-12 23357778 PMC3623344 · DOI
  105. [111]Talseth T. Kinetics of hydralazine elimination. Clin Pharmacol Ther 1977; 21: 715- 20. 10.1002/cpt1977216715 862310 · DOI
  106. [112]Turnheim K Krivanek P Oberbauer R. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. Br J Clin Pharmacol 1999; 48: 501- 9. 10.1046/j.1365-2125.1999.00041.x 10583019 PMC2014375 · DOI
  107. [113]Wang Y Gray JP Mishin V Role of cytochrome P450 reductase in nitrofurantoin-induced redox cycling and cytotoxicity. Free Radic Biol Med 2008; 44: 1169- 79. 10.1016/j.freeradbiomed.2007.12.013 18206659 PMC5793909 · DOI
  108. [114]Yamazaki H Shimada T. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys 1997; 346: 161- 9. 10.1006/abbi.1997.0302 9328296 · DOI · Paper page
  109. [115]Yu K Geng X Chen M High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury. Drug Metab Dispos 2014; 42: 744- 50. 10.1124/dmd.113.056267 24464804 · DOI
  110. [116]Zanger UM Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013; 138: 103- 41. 10.1016/j.pharmthera.2012.12.007 23333322 · DOI · Paper page
  111. [117]Brunell D Sagher D Kesaraju S Studies on the metabolism and biological activity of the epimers of sulindac. Drug Metab Dispos 2011; 39: 1014- 21. 10.1124/dmd.110.037663 21383205 PMC3100905 · DOI
  112. [118]Nielsen TL Rasmussen BB Flinois JP In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes. J Pharmacol Exp Ther 1999; 289: 31- 7. 10086984
  113. [119]Guengerich FP. Mechanisms of cytochrome P450 substrate oxidation: MiniReview. J Biochem Mol Toxicol 2007; 21: 163- 8. 10.1002/jbt.20174 17936929 · DOI
  114. [120]Fu S Wu D Jiang W Molecular biomarkers in drug-induced liver injury: challenges and future perspectives. Front Pharmacol 2020; 10: 1667. 10.3389/fphar.2019.01667 32082163 PMC7002317 · DOI
  115. [121]Uetrecht JP. New concepts in immunology relevant to idiosyncratic drug reactions: the “danger hypothesis” and innate immune system. Chem Res Toxicol 1999; 12: 387- 95. 10.1021/tx980249i 10328748 · DOI
  116. [122]Kumar S. Plasma exosomes and drug metabolic cytochrome p450 enzymes. J Drug Metab Toxicol 2015; 6: 5671.
  117. [123]Kumar S Sinha N Gerth KA Specific packaging and circulation of cytochromes P450, especially 2E1 isozyme, in human plasma exosomes and their implications in cellular communications. Biochem Biophys Res Commun 2017; 491: 675- 80. 10.1016/j.bbrc.2017.07.145 28756226 PMC5901973 · DOI
  118. [124]Metushi IG Sanders C Acute LSG Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure. Hepatology 2014; 59: 1084- 93. 10.1002/hep.26564 23775837 PMC4940023 · DOI
  119. [125]Obermayer-Straub P Strassburg CP Manns MP. Target proteins in human autoimmunity: cytochromes P450 and UDP-glucuronosyltransferases. Can J Gastroenterol 2000; 14: 429- 39. 10.1155/2000/910107 10851284 · DOI
  120. [126]Sutti S Rigamonti C Vidali M CYP2E1 autoantibodies in liver diseases. Redox Biol 2014; 3: 72- 8. 10.1016/j.redox.2014.11.004 25462068 PMC4297929 · DOI
  121. [127]Mosedale M Watkins PB. Drug-induced liver injury: Advances in mechanistic understanding that will inform risk management. Clin Pharmacol Ther 2017; 101: 469- 80. 10.1002/cpt.564 27861792 PMC5359062 · DOI
  122. [128]Boelsterli UA Lee KK. Mechanisms of isoniazid-induced idiosyncratic liver injury: emerging role of mitochondrial stress. J Gastroenterol Hepatol 2014; 29: 678- 87. 10.1111/jgh.12516 24783247 · DOI
  123. [129]Kaplowitz N. Avoiding idiosyncratic DILI: two is better than one. Hepatology 2013; 58: 15- 7. 10.1002/hep.26295 23390057 · DOI
  124. [130]Ye H Nelson LJ Gómez Del Moral M Dissecting the molecular pathophysiology of drug-induced liver injury. World J Gastroenterol 2018; 24: 1373- 85. 10.3748/wjg.v24.i13.1373 29632419 PMC5889818 · DOI
  125. [132]Boelsterli UA. Acyl glucuronides: mechanistic role in drug toxicity. Curr Drug Metab 2011; 12: 213- 4. 10.2174/138920011795101831 21395537 · DOI
  126. [134]McGill MR Jaeschke H. Animal models of drug-induced liver injury. Biochim Biophys Acta Mol Basis Dis 2019; 1865: 1031- 9. 10.1016/j.bbadis.2018.08.037 31007174 PMC6478394 · DOI
  127. [135]Pan Y Cao M You D Research progress on the animal models of drug-induced liver injury: current status and further perspectives. Biomed Res Int 2019; 2019: 1283824. 10.1155/2019/1283824 31119149 PMC6500714 · DOI
  128. [136]Ghahremanloo A Soltani A Modaresi SMS Recent advances in the clinical development of immune checkpoint blockade therapy. Cell Oncol (Dordr) 2019; 42: 609- 26. 10.1007/s13402-019-00456-w 31201647 PMC12994343 · DOI
  129. [137]Suzman DL Pelosof L Rosenberg A Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int 2018; 38: 976- 87. 10.1111/liv.13746 29603856 · DOI · Paper page
  130. [138]Metushi IG Hayes MA Uetrecht J. Treatment of PD-1(-/-) mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients. Hepatology 2015; 61: 1332- 42. 10.1002/hep.27549 25283142 · DOI
  131. [139]Mak A Uetrecht J. The Role of CD8 T cells in amodiaquine-induced liver injury in PD1-/- Mice cotreated with anti-CTLA-4. Chem Res Toxicol 2015; 28: 1567- 73. 10.1021/acs.chemrestox.5b00137 26154582 · DOI
  132. [140]Mak A Uetrecht J. The combination of anti-CTLA-4 and PD1-/- mice unmasks the potential of isoniazid and nevirapine to cause liver injury. Chem Res Toxicol 2015; 28: 2287- 91. 10.1021/acs.chemrestox.5b00305 26529122 · DOI

Cited by

Sorted by citations

Metadata

Authors
Teschke, R., & Uetrecht, J.
Venue
Annals of Translational Medicine
Publisher
AME Publishing Company
Published
2021-04
Volume
9
Issue
8
Pages
730-730
ISSN
  • 2305-5839
  • 2305-5847
DOI
10.21037/atm-2020-ubih-05
PMC
PMC8106057
Cited by
58
References
6

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review